Applied Biometrics to shut down and sell assets
This article was originally published in Clinica
Applied Biometrics is to close its business operations and attempt to dispose of its remaining assets after conceding that technical problems with its cardiac output monitor are "well beyond our financial capabilities to resolve".
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.